Home Ingredients AHCC (Active Hexose Correlated Compound)
Immune SupportWomen's Health

AHCC (Active Hexose Correlated Compound)

Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

AHCC is a proprietary FERMENTED MUSHROOM MYCELIUM EXTRACT — primarily from shiitake (Lentinula edodes) and other basidiomycetes — developed by Amino Up Co. (Japan) since 1989. Distinguished from whole mushroom extracts by acetylated alpha-glucan (rather than typical beta-glucan) as primary active. Most clinically-studied for HPV (human papillomavirus) clearance, immune support during chemotherapy, and infection adjunct. Substantial clinical research base for a mushroom-derived supplement.

Studied Dose 1-3 g/day; 3 g/day used in HPV clearance trials (Smith 2019 — 6 months); 1-3 g/day for immune support
Active Compound Alpha-glucan oligosaccharides (acetylated; ~20% of extract); other polysaccharides

Benefits

HPV Clearance (Smith 2019 Pilot)

Smith 2019 pilot trial of AHCC (3 g/day for 6 months) in 22 women with persistent HPV infection — 41% achieved HPV clearance + sustained negative for 6 months. Phase 2 RCT (NCT02405533) ongoing. Notable as one of few supplements with prospective HPV clearance evidence.

Supported by Trial 1

Chemotherapy Adjunct (Quality of Life, Outcomes)

Multiple Japanese trials show AHCC improves QoL during chemotherapy, reduces side effects, and may improve outcomes in liver cancer (HCC) and other cancers. Used widely in Japanese integrative oncology.

Supported by Trial 2

Immune Cell Activation

Increases NK cell activity, T-cell function, dendritic cell function. Mechanism well-characterized. Modest but real immune activation.

Liver Function Protection

Some evidence for hepatoprotective effects, particularly during chemotherapy and viral hepatitis. Cohen 2017 trial showed reduced liver enzyme elevation during interferon therapy.

Supported by Trial 2

Infection Adjunct (Various)

Some evidence for modest adjunctive benefit in influenza, HIV (immune support), and other chronic infections. Not standalone treatment for these conditions.

Supported by Trial 1, Trial 2

Mechanism of action

1

Acetylated Alpha-Glucan Active

AHCC's distinctive feature is acetylated alpha-glucan oligosaccharides (~20% of extract) — DIFFERENT from typical mushroom beta-glucans (lentinan, MD-fraction, etc.). Theoretical advantage: alpha-glucan oligosaccharides may have better oral absorption than complex beta-glucan polymers.

2

NK Cell Activation

Increases natural killer (NK) cell activity — innate immune response important for viral infection and tumor surveillance. Multiple trials confirm NK activation.

3

Dendritic Cell Function

Activates dendritic cells — antigen-presenting cells that bridge innate and adaptive immunity. Important for sustained immune responses.

4

Cytokine Modulation

Modulates inflammatory cytokine balance — typically increases Th1 (cellular immunity) cytokines while modulating inflammatory response. Different from indiscriminate immune stimulation.

Clinical trials

1
AHCC for HPV Clearance — Smith 2019 Pilot
PubMed

Open-label pilot trial of AHCC (3 g/day) for 6 months in 22 women with persistent HPV infection. UT Health Science Center.

22 women with persistent HPV infection.

9 of 22 patients (41%) achieved durable HPV clearance + sustained negative for 6 months post-supplementation. Generated significant interest. Larger phase 2 RCT ongoing (NCT02405533).

2
AHCC for Liver Cancer Outcomes — Cowawintaweewat 2006 / Matsui 2002
PubMed

Multiple Japanese trials of AHCC as adjunct in hepatocellular carcinoma (HCC) patients post-resection.

Liver cancer patients.

Improved overall survival, recurrence-free survival, and QoL vs control in some trials. Established AHCC in Japanese integrative oncology.

Side effects and drug interactions

Common Potential side effects

Generally very well-tolerated.
Mild GI distress (nausea, diarrhea, gas) — particularly during initial use.
Headache rare.
Allergic reactions to mushroom rare.
Caution in autoimmune disease (theoretical immune activation concern).
AVOID in transplant patients without medical supervision.

Important Drug interactions

Chemotherapy — used adjunctively in Japan; consult oncologist for specific regimens.
Immunosuppressants — AVOID in transplant patients without medical supervision; immune activation opposes intentional immunosuppression.
Anticoagulants — theoretical minor bleeding risk.
Other immune-modulating supplements — additive effects.
CYP3A4 substrates — potentially modest effects (limited data).

More Immune Support Ingredients

Bone Health
Vitamin D
Vitamin D, often supplied in supplements as cholecalciferol (D3) or ergocalciferol (D2), i…
Immune Support
EpiCor® (Postbiotic Yeast Fermentate — Cargill)
EpiCor® is a SCIENCE-BACKED POSTBIOTIC INGREDIENT from Cargill — derived from the fermenta…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…
Immune Support
BLIS K12® (Streptococcus salivarius for ENT — Stratum Nutrition)
BLIS K12® is a PROPRIETARY STREPTOCOCCUS SALIVARIUS PROBIOTIC STRAIN developed by Blis Tec…

Explore Other Ingredients

Women's Health
DIM (Diindolylmethane)
DIM (3,3'-diindolylmethane) is a metabolite of indole-3-carbinol (I3C) — formed in the sto…
Cognitive
Pregnenolone
Pregnenolone is a STEROID HORMONE PRECURSOR — synthesized from cholesterol in adrenals, go…
Women's Health
Libifem® (Fenugreek for Female Libido)
Libifem® is the SAME STANDARDIZED FENUGREEK SEED EXTRACT as Testofen® (Fenuside™ furostano…

Frequently asked questions about AHCC (Active Hexose Correlated Compound)

What is the recommended dosage of AHCC (Active Hexose Correlated Compound)?

The clinically studied dose for AHCC (Active Hexose Correlated Compound) is 1-3 g/day; 3 g/day used in HPV clearance trials (Smith 2019 — 6 months); 1-3 g/day for immune support. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is AHCC (Active Hexose Correlated Compound) used for?

AHCC (Active Hexose Correlated Compound) is studied for hpv clearance (smith 2019 pilot), chemotherapy adjunct (quality of life, outcomes), immune cell activation. Smith 2019 pilot trial of AHCC (3 g/day for 6 months) in 22 women with persistent HPV infection — 41% achieved HPV clearance + sustained negative for 6 months. Phase 2 RCT (NCT02405533) ongoing.

Are there side effects from taking AHCC (Active Hexose Correlated Compound)?

Reported potential side effects may include: Generally very well-tolerated. Mild GI distress (nausea, diarrhea, gas) — particularly during initial use. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does AHCC (Active Hexose Correlated Compound) interact with medications?

Known drug interactions may include: Chemotherapy — used adjunctively in Japan; consult oncologist for specific regimens. Immunosuppressants — AVOID in transplant patients without medical supervision; immune activation opposes intentional immunosuppression. Consult a pharmacist or healthcare provider if you take prescription medications.

Is AHCC (Active Hexose Correlated Compound) good for immune support?

Yes, AHCC (Active Hexose Correlated Compound) is researched for Immune Support support. Increases NK cell activity, T-cell function, dendritic cell function. Mechanism well-characterized. Modest but real immune activation.